What this is
- This study investigates a new headache category termed '' () in children and adolescents.
- Conducted in Turkey, it involved a nationwide survey of 7889 pupils aged 6-17 years.
- is characterized by recurrent mild headaches lasting less than 1 hour and is common among this population.
Essence
- affects 29.2% of children and adolescents in Turkey, differing significantly from migraine and tension-type headache (TTH) in features and impact on quality of life (QoL).
Key takeaways
- prevalence is 29.2%, higher than TTH (12.9%) and comparable to migraine (26.7%). This indicates a significant burden of headache types not fitting existing diagnostic criteria.
- shows lower headache frequency and intensity compared to migraine and TTH, impacting school attendance and emotional well-being less severely.
- Quality of life scores for (33.6 ± 5.2) are better than those for migraine (30.3 ± 5.6) and TTH (32.4 ± 5.3), but worse than pupils without headaches (35.7 ± 4.7).
Caveats
- The study's convenience sampling may limit the generalizability of findings, particularly regarding urban representation.
- Reliance on self-reported data could introduce recall bias, affecting the accuracy of headache prevalence and characteristics.
Definitions
- undifferentiated headache (UdH): Recurrent mild-intensity headache lasting less than 1 hour, not fitting specific diagnostic criteria for migraine or TTH.
AI simplified
Background
In the Global Burden of Disease Study 2010 (GBD2010) [1], tension-type headache (TTH) and migraine were revealed as second and third most prevalent disorders in the world. In GBD2013, headache disorders collectively were third among the leading causes of disability [2]. In GBD2016, migraine came top – the single most disabling disorder – in the age group 15–49 years [3].
The data underpinning these statistics were derived in the main from studies in adults aged 18–65 years. In children (6–11 years) and adolescents (12–17 years), the prevalence of headache disorders is not well established and the burdens attributable to them are poorly characterised. Multiple factors explain this. First, there are relatively few published epidemiological studies [4] and, second, most of these have been conducted in middle- or high-income Western countries, leaving very large geographical gaps [4]. Third, substantial methodological differences between them limit their comparability. Nonetheless, extrapolations to these age groups in these global surveys put migraine among the top 10 global causes of years lived with disability (YLDs) in the 50 most populous countries [5].
An additional factor arises from the operational diagnostic criteria set out in the universally accepted International Classification of Headache Disorders (ICHD), now in its third edition (ICHD-3) [6]. While ICHD recognises > 200 headache disorders, only migraine and TTH among the primary headache disorders have public-health importance [1–4]. Medication-overuse headache (MOH), with an adult mean global prevalence of 1.5–2% [7], also contributes substantially to global disability [2, 3]. The ICHD diagnostic criteria for migraine in adults specify recurrent moderate-to-severe headache of 4–72 h’ duration, with a range of specific characteristics (unilaterality, pulsating quality, aggravation by physical activity) and accompanying symptoms (photophobia and phonophobia; nausea and/or vomiting) [6]. In children it is noted that the headache may be of shorter duration (2–72 h). The criteria for TTH specify mild-to-moderate headache lasting from 30 min to 7 days, with neither the specific characteristics nor the accompanying symptoms of migraine [6]. In our pilot school-based prevalence survey conducted in Turkey and Austria, mild headache of < 1 h’s duration was reported by a large proportion (37.2%) of participants aged 6–17 years, often with migraine-like features [8].
Such headache could not be given a definite diagnosis of migraine or, when there were migraine-like features, of TTH. Furthermore, although ICHD criteria for TTH have, from the first edition onwards [9], specified a lower duration limit of 30 min, we questioned whether this disorder existed in a form in which headache was typically of < 1 h’s duration. Therefore, in the context of epidemiological studies, we found ourselves in doubt as to how this common presentation of headache should be labelled.
The literature offered no guidance. In the most recent survey [10] and a Medline search (using the terms “migraine”, “tension-type headache”, “children”, “adolescents”, “prevalence” and “epidemiology” without language restrictions), we found 59 relevant studies. The majority (54: 91.5%) reported only selected diagnoses (most often definite migraine), and, crucially, did not specify the proportion of unclassifiable headaches. However, among the five studies that did report them [11–15], unclassifiable headaches were common, with an average prevalence of almost 20%. In other words, the problem we encountered had been recognised previously – but ignored.
In the present study, we investigate whether a new approach is required in children and adolescents, recognising that the characteristics of adult migraine (and perhaps TTH) may be undeveloped in 6–17 year-olds. We introduce an additional diagnostic category defined by headache duration of < 1 h and mild intensity, which we have termed “undifferentiated headache” (UdH). In a nationwide school-based epidemiological survey in Turkey, we compare the clinical features of UdH with those of migraine and TTH. We also compare the burdens attributable to each, including impact on quality of life (QoL). Our purpose is to establish whether or not UdH should be regarded for epidemiological and perhaps clinical purposes as distinct from migraine and TTH.
The survey was conducted under the auspices of the Global Campaign against Headache [16], which is directed by the UK-registered non-governmental organisation Lifting The Burden (LTB) in official relations with the World Health Organization [17], and of Dr. Gönül Bingöl-Dr Muammer Bingöl Çocuk ve Ergen Başağrısı Derneği.
Methods
Ethics and approvals
The protocol was approved by the ethics committee of the co-ordinating centre (Istanbul University no. 83045809/604/02–12,472). Since the study involved multiple schools nationwide, approval was also obtained from the Ministry of National Education. Copies of these approvals were sent to the school managers to obtain permissions to visit.
Informed consent, in terms agreed within these approvals, was given by or on behalf of each child or adolescent before his or her participation.
Data were collected anonymously and managed in accordance with data-protection legislation.
Study design
The cross-sectional survey applied the methods developed and tested in pilot studies performed in Istanbul and Vienna [8]. Conducted nationwide in selected schools, it employed a self-completed structured questionnaire administered to entire classes. It was performed within one academic term, avoiding examination periods, between April 4th and June 13th 2014.
Sampling and subjects
We used mixed convenience-based and purposive modified cluster-sampling. The procedure was multistage: (1) selection of sites in each of six regions of Turkey, reflecting the country’s geographical and socioeconomic diversity; (2) identification by the local investigators of three or more schools within each site to reflect, as far as possible, its socioeconomic and urban/rural diversity; (3) selection of classes in each school across the age ranges 6–11 and/or 12–17 years (randomly, when there were more than one for any particular year); and (4) inclusion of all eligible children in the classes.
The survey sites were six cities and their environs: Elâzığ (eastern Anatolia, in uppermost Euphrates valley); Hatay (southern Turkey, close to the Syrian border) Istanbul (north-western Turkey, astride the Bosphorus); Muğla (south-western Turkey, close to the Aegean coast); Rize (north-eastern Turkey, on the Black Sea coast), and Tekirdağ (European side, on the northern coast of the Sea of Marmara).
Selected schools were invited to participate. Within each class, all eligible pupils were included except for those who refused, were unable to take part for any reason, or were absent from school on the interview day.
Questionnaires
The questionnaire was an adaptation of the HARDSHIP questionnaire [18] in separate versions for children and adolescents. These were translated into Turkish language in accordance with LTB’s translation protocol for hybrid documents to capture exact meaning rather than simple linguistic equivalence [19]. Each version had been evaluated with satisfactory results in the pilot studies [8], requiring < 30 min to complete. The questionnaires were administered to the pupils in class by trained medical residents, introduced by their teacher (the mediator). The mediator took steps to prevent any participant copying the responses of another.
Questions were included on demographics, headache occurrence, ICHD-3 beta diagnostic criteria (no different, with respect to migraine and TTH, from those of ICHD-3 [6]), burden attributable to headache, and QoL. A short questionnaire completed by the mediator recorded details about the school and its local environment. A further very brief questionnaire also completed by the mediator documented non-participation. Both these questionnaires have been published previously [8].
Headache diagnosis
Diagnoses were made using the HARDSHIP algorithm [18], but we modified the process to include UdH. First, we applied the criteria for UdH (duration < 1 h, intensity mild). Among remaining participants, we separated those reporting headache on ≥15 days/month, diagnosing probable MOH (pMOH) when acute medication was reportedly used on ≥15 days/month or, otherwise, “other headache on ≥15 days/month” (these cases were not included in this analysis). To those still remaining (with episodic headache of duration ≥1 h and/or intensity moderate or severe), we applied the criteria, in order, for definite migraine, definite TTH, probable migraine and finally probable TTH [20]; criterion B for TTH [6] was modified by raising the lower limit of duration to 1 h.
Statistics and analyses
Recommendations on sample-size calculation for headache prevalence suggest limited gain from samples of > 2000 participants [20]. For burden, larger numbers may be more informative, but there is no good basis for power calculation. We aimed for 4000 evaluable participants per age range, spread as evenly overall as possible by recruiting across the age groups in each school.
Completed questionnaires were conveyed to and held securely at Istanbul University, where data were transferred into a secure electronic database.
Many questions required “yes/no” responses. Headache duration was reported in hours and intensity as “not bad”, “quite bad” or “very bad”, which we equated to mild, moderate and severe. Frequencies were reported in days per week or 4 weeks. Emotional impact and QoL questions required selection from the response options “never”, “sometimes”, “often” and “always” in the preceding 4 weeks; these were scored 1–4, and summed to generate impact (potential range 6–24; high being adverse) and QoL scores (12–48; low being adverse).
For descriptive analyses we generated proportions (%) and, where appropriate, means and standard deviations (SDs). In comparative analyses, we applied Student’s t-test to parametric variables, Kruskal Wallis test to nonparametric continuous variables and chi-squared test to categorical variables. We used bivariate analysis to estimate odds ratios (ORs) with 95% confidence intervals (CIs).
We used IBM SPSS Statistics, Version 23, for all calculations. To adjust for multiple comparisons, Bonferroni correction was performed online [21] following the suggestions of Sankoh et al. [22]. In the case of correlated outcome variables, Bonferroni correction is too conservative; the variables in our study were highly correlated with each other: calculating Pearson correlation coefficients we found a statistically significant correlation in 227 of 253 correlations (90%). Therefore, the p-value for significance required adjustment only to p < 0.03.
Results
Study population
We invited 31 schools (2–10 [mean 5.2 ± 2.6] per site), 288 classes (2–32 [mean 9.4 ± 6.6] per school) and 7889 pupils (3–167 [27.4 ± 16.1] per class). None of the invited schools or classes declined to participate. Of the 7889 invited pupils, 7088 (89.8%) participated and 7068 (99.7%; 89.6% overall) completed questionnaires were evaluable (2551 children, 4517 adolescents). We did not achieve the intended N = 4000 children because of skewed age-distributions within the schools. Mean participation proportion of pupils per class was 90.8 ± 12.1% with no gender difference (girls 91.1 ± 14.4%; boys 90.5 ± 13.6%) and similar across age-groups (lowest [86.9 ± 17.7%] in pupils aged 15–16 and highest [95.1 ± 5.6%] in those aged 11–12 years). Pupil numbers per site ranged from 578 to 1855, and per age group from 290 (6–7 years) to 1146 (13–14 years).
Reasons for non-participation in the 10.2% were inadequately established despite the mediator’s questionnaire for this purpose, and cannot be reported.
Schools
The proportions of schools in urban, semiurban and rural regions were 42.4%, 43.1% and 14.6% (compared with national urban and rural proportions extrapolated from 2011 data of about 77% and 23% [23]). The proportions in high-income, upper middle-, lower middle- and low-income districts were 2.8%, 27.1%, 68.4% and 1.7%.
Headache prevalence
Headache during the previous year was reported by 73.7% of participants. We found the following 1-year prevalences: UdH 29.2%; migraine 26.7% (7.3% definite, 19.4% probable); TTH 12.9% (definite 6.7%, probable 6.2%); pMOH 0.9%; other headache on ≥15 days/month 3.4%; unclassifiable headache 0.5%. With concern for possible interest bias among responders, we also calculated prevalences with reference to the target sample of 7889 pupils: UdH 26.2%; migraine 23.9% (definite 6.5%, probable 17.4%); TTH 11.6% (definite 6.2%, probable 5.4%); pMOH 0.8%; other headache on ≥15 days/month 3.0%; unclassifiable headache 0.5%.
Further analyses focus on UdH, migraine and TTH, combining definite and probable cases of the latter two as recommended in guidelines [20].
Headache characteristics and associated symptoms
Classifying UdH according to frequency analogously to TTH, we recorded infrequent episodic UdH in 26.7%, frequent episodic UdH in 72.0% and chronic UdH in 1.3% of cases.
UdH differed with respect to almost all headache features and associated symptoms from both migraine and TTH (Table 1). Headache days both in the previous week and in the previous 4 weeks were fewer in UdH than in migraine and TTH; in keeping with this, headache yesterday was less common in UdH than in migraine and TTH (Table 2). Intensity of headache yesterday was lower in UdH than in migraine and TTH. In contrast to the general rating of headache intensity as mild in UdH, 16.3% of pupils with the diagnosis of UdH rated headache yesterday as moderate or severe (Table 2).
| Undifferentiated headache | Migrainea | Tension-type headachea | Undifferentiated headache vs migrainea | Undifferentiated headache vs tension-type headachea | ||||||
|---|---|---|---|---|---|---|---|---|---|---|
| = 2066N | = 1888N | = 911N | OR [95% CI] | pb | OR [95% CI] | pb | ||||
| n | % | n | % | n | % | |||||
| Headache in previous week | 2036 | 1864 | 899 | |||||||
| No | 949 | 46.6 | 417 | 22.4 | 322 | 35.8 | reference | reference | ||
| ≥ 1 day | 1087 | 53.4 | 1447 | 77.6 | 577 | 64.2 | 0.33 [0.29–0.38] | < 0.001 | 0.64 [0.54–0.75] | < 0.001 |
| Headache in previous 4 weeks | 2050 | 1880 | 898 | |||||||
| No | 548 | 26.7 | 207 | 11 | 161 | 17.9 | reference | reference | ||
| ≥ 1 day | 1502 | 73.3 | 1673 | 89 | 737 | 82.1 | 0.34 [0.29–0.40] | < 0.001 | 0.60 [0.49–0.73] | < 0.001 |
| Duration (hr) | 2066 | 1877 | 910 | |||||||
| < 1 | 2066 | 100 | 317 | 16.9 | 145 | 15.9 | NA | NA | NA | NA |
| 1–2 | 0 | 0 | 989 | 52.7 | 657 | 7.2 | ||||
| > 2 and < 4 | 0 | 0 | 370 | 19.7 | 77 | 8.5 | ||||
| ≥ 4 | 0 | 0 | 201 | 10.7 | 31 | 3.4 | ||||
| Intensity | 2066 | 1877 | 907 | |||||||
| Mild | 2066 | 100 | 537 | 28.5 | 516 | 56.9 | NA | NA | NA | NA |
| Moderate | 0 | 0 | 1046 | 55.4 | 319 | 35.2 | ||||
| Severe | 0 | 0 | 304 | 16.1 | 72 | 7.9 | ||||
| Quality | 2044 | 1885 | 908 | |||||||
| Pulsating | 1437 | 70.3 | 1478 | 78.4 | 555 | 61.1 | reference | reference | ||
| Pressing | 607 | 29.7 | 407 | 21.6 | 353 | 38.9 | 1.5 [1.3–1.8] | < 0.001 | 0.66 [0.56–0.78] | < 0.001 |
| Localisation | 2048 | 1887 | 906 | |||||||
| Unilateral | 645 | 31.5 | 463 | 24.5 | 158 | 17.4 | 0.90 [0.76–1.07] | NS | 1.7 [1.4–2.1] | < 0.001 |
| Middle | 652 | 31.8 | 421 | 22.3 | 269 | 29.7 | reference | reference | ||
| Bilateral | 751 | 36.7 | 1003 | 53.2 | 479 | 52.9 | 0.48 [0.41–0.56] | < 0.001 | 0.65 [0.54–0.78] | < 0.001 |
| Aggravation by physical activity | 2059 | 1886 | 910 | |||||||
| No | 1356 | 65.9 | 596 | 31.6 | 509 | 55.9 | reference | reference | ||
| Yes | 703 | 34.1 | 1290 | 68.4 | 401 | 44.1 | 0.24 [0.21–0.27] | < 0.001 | 0.66 [0.56–0.77] | < 0.001 |
| Avoidance of physical activity | 2060 | 1888 | 911 | |||||||
| No | 1009 | 49 | 319 | 16.9 | 408 | 44.8 | reference | reference | ||
| Yes | 1051 | 51 | 1569 | 83.1 | 503 | 55.2 | 0.21 [0.18–0.25] | < 0.001 | 0.85 [0.72–0.99] | 0.04 |
| Nausea | 2053 | 1887 | 909 | |||||||
| No | 1381 | 67.3 | 578 | 30.6 | 751 | 82.6 | reference | reference | ||
| Yes | 672 | 32.7 | 1309 | 69.4 | 158 | 17.4 | 0.22 [0.19–0.25] | < 0.001 | 2.3 [1.9–2.8] | < 0.001 |
| Vomiting | 2054 | 1887 | 902 | |||||||
| No | 1842 | 89.7 | 1364 | 72.3 | 845 | 93.7 | reference | reference | ||
| Yes | 212 | 10.3 | 523 | 27.7 | 57 | 6.3 | 0.30 [0.25–0.36] | < 0.001 | 1.7 [1.3–2.3] | < 0.001 |
| Photophobia | 2058 | 1883 | 908 | |||||||
| No | 1385 | 67.3 | 622 | 33 | 752 | 82.8 | reference | reference | ||
| Yes | 673 | 32.7 | 1261 | 67 | 156 | 17.2 | 0.24 [0.21–0.24] | < 0.001 | 2.3 [1.9–2.9] | < 0.001 |
| Phonophobia | 2062 | 1887 | 909 | |||||||
| No | 257 | 12.5 | 72 | 3.8 | 125 | 13.8 | reference | reference | ||
| Yes | 1805 | 87.5 | 1815 | 96.2 | 784 | 86.2 | 0.28 [0.21–0.37] | < 0.001 | 1.1 [0.89–1.4] | 0.3 |
| Headache yesterday | Undifferentiated headache | Migrainea | Tension-type headachea | Undifferentiated headache vs migrainea | Undifferentiated headache vs tension-type headachea | |||||
|---|---|---|---|---|---|---|---|---|---|---|
| = 2066N | = 1888N | = 911N | OR [95% CI] | pb | OR [95% CI] | pb | ||||
| n | % | n | % | n | % | |||||
| Present | 2027 | 1872 | 895 | |||||||
| No | 1624 | 80.1 | 1053 | 56.3 | 645 | 72.1 | reference | |||
| Yes | 403 | 19.9 | 819 | 43.7 | 250 | 29.9 | 0.32 [0.28–0.37] | < 0.001 | 0.64 [0.56–0.77] | < 0.001 |
| Intensity | 403 | 819 | 250 | |||||||
| Mild | 328 | 83.7 | 408 | 50.6 | 151 | 62.7 | 3.9 [2.8–5.4] | < 0.001 | 2.8 [1.9–4.2] | < 0.001 |
| Moderate | 55 | 14 | 265 | 32.9 | 72 | 29.9 | reference | reference | ||
| Severe | 9 | 2.3 | 133 | 1.5 | 18 | 7.4 | 0.33 [0.16–0.68] | 0.002 | 0.66 [0.27–1.6] | 0.3 |
| Loss of lessons at school | 403 | 819 | 250 | |||||||
| No | 360 | 90.2 | 693 | 87.3 | 217 | 89.7 | reference | reference | ||
| Yes | 39 | 9.8 | 101 | 12.7 | 25 | 10.3 | 0.74 [0.50–1.1] | 0.1 | 0.94 [0.55–1.6] | 0.8 |
ICHD criteria
Criterion B (duration < 1 h) was predefined for UdH. Criterion C for migraine without aura was fulfilled by 57.4% of UdH cases and criterion C for episodic TTH by 86.1%. Criterion D for each was fulfilled by 55.1% and 44.9% of UdH cases. The proportions of pupils with UdH fulfilling none, one or two of criteria C and D for migraine without aura were 20.7%, 45.7% and 33.5%. The proportions who fulfilled none, one or two of criteria C and D for episodic TTH were 8.7%, 52.0% and 39.3%.
Burden of headache
The proportions of pupils who missed school lessons because of headache yesterday did not differ between the three groups (Table 2), but impact on school attendance and leisure-time activities in the preceding 4 weeks was lower in UdH than in migraine and TTH. UdH was less likely than migraine, but not TTH, to cause a parent to leave work (Table 3).
UdH imposed less emotional impact (summed impact score 11.3 ± 2.7) than migraine (13.6 ± 3.0; p < 0.001) and TTH (11.9 ± 2.7; p < 0.001).
| Burden measure | Undifferentiated headache | Migrainea | Tension-type headachea | Undifferentiated headache vs migrainea | Undifferentiated headache vs tension-type headachea | |||||
|---|---|---|---|---|---|---|---|---|---|---|
| = 2066N | = 1888N | = 911N | OR [95% CI] | pb | OR [95% CI] | pb | ||||
| n | % | n | % | n | % | |||||
| School absence | 2046 | 1866 | 900 | |||||||
| No | 1792 | 87.6 | 1439 | 76.2 | 753 | 83.7 | reference | reference | ||
| ≥ 1 day | 254 | 12.4 | 427 | 23.8 | 147 | 16.3 | 0.48 [0.40–0.57] | < 0.001 | 0.73 [0.59–0.91] | 0.004 |
| School left early | 1997 | 1818 | 884 | |||||||
| No | 1819 | 91.1 | 1479 | 81.4 | 766 | 86.7 | reference | reference | ||
| ≥ 1 day | 17 | 8.9 | 339 | 18.6 | 118 | 13.3 | 0.43 [0.35–0.52] | < 0.001 | 0.64 [0.50–0.81] | < 0.001 |
| Impact on activity | 2015 | 1800 | 887 | |||||||
| No | 1261 | 62.6 | 582 | 32.3 | 459 | 51.7 | reference | reference | ||
| ≥ 1 day | 754 | 37.4 | 1218 | 67.7 | 428 | 48.3 | 0.29 [0.25–0.33] | < 0.001 | 0.64 [0.55–0.75] | < 0.001 |
| Parent took work leave | 2044 | 1880 | 902 | |||||||
| No | 1906 | 93.2 | 1607 | 85.5 | 832 | 92.2 | reference | reference | ||
| ≥ 1 Day | 138 | 6.8 | 273 | 14.5 | 70 | 7.8 | 0.43 [0.34–0.53] | < 0.001 | 0.86 [0.64–1.2] | 0.3 |
Quality of life
UdH adversely affected QoL (summed QoL score 33.6 ± 5.2 versus 35.7 ± 4.7 [p < 0.001] in pupils without headache), but to a lesser extent than migraine (30.3 ± 5.6; p < 0.001) and TTH (32.4 ± 5.3; p < 0.001).
Use of acute medication
Pupils with UdH took acute medication on fewer days than those with migraine or TTH. Nevertheless, large proportions of those with UdH reported use of acute medication in the previous week (38.9%) and 4 weeks (43.2%) (Table 4).
| Use of acute medication | Undifferentiated headache | Migrainea | Tension-type headachea | Undifferentiated headache vs migrainea | Undifferentiated headache vs tension-type headachea | |||||
|---|---|---|---|---|---|---|---|---|---|---|
| = 2066N | = 1888N | = 911N | OR [95% CI] | pb | OR [95% CI] | pb | ||||
| n | % | n | % | n | % | |||||
| Previous week | 1074 | 1390 | 566 | |||||||
| None | 656 | 61.1 | 555 | 39.9 | 279 | 49.3 | reference | reference | ||
| ≥ 1 day | 418 | 38.9 | 835 | 60.1 | 2873 | 50.7 | 0.42 [0.36–0.50] | < 0.001 | 0.62 [0.50–0.76] | < 0.001 |
| Previous 4 weeks | 1490 | 1620 | 725 | |||||||
| None | 846 | 56.8 | 513 | 31.7 | 324 | 44.7 | reference | reference | ||
| ≥ 1 day | 644 | 43.2 | 1107 | 68.3 | 401 | 55.3 | 0.35 [0.31–0.41] | < 0.001 | 0.62 [0.51–0.76] | < 0.001 |
Discussion
In this large nationwide sample of pupils aged 6–17 years in Turkey, we identified a headache type which we termed “undifferentiated headache” (UdH). UdH differed measurably with respect to almost all headache features and associated symptoms from both migraine and TTH. Although characterised by mild headaches lasting < 1 h, UdH was associated with significant burden, including adverse impact on QoL. Crucially, UdH was common, affecting almost 30% of the pupils.
It is arguable that UdH meeting two criteria of migraine without aura (as did one third of the cases diagnosed as UdH) might better be classified as probable migraine, and UdH meeting two criteria of TTH (almost 40% of cases) might better be classified as probable TTH. Longitudinal studies suggest, however, that a considerable proportion (8.3–71%) of children and adolescents with migraine evolve to TTH or vice versa [24]. In a 7-month follow-up study, diagnostic stability was higher in definite migraine (76.7%) and definite TTH (57.1%) than in probable migraine (44.7%) or probable TTH (43.3%) [25]. The findings of our study reflect this, and support the concept of UdH as a more appropriate diagnosis among these age groups than probable migraine or probable TTH.
With respect to headache duration, in order to accommodate the diagnosis of UdH, we necessarily modified the ICHD criteria for TTH, raising the minimum duration from 30 min to 1 h. As we noted earlier, we question whether TTH – in children or adults – really exists in a form in which headache of < 1 h’s duration is typical. Although epidemiological studies indicate that it does, we suggest that such reported occurrences are the consequence of treatment: many participants may not have experienced untreated attacks for many years [20].
In previous epidemiological studies of headache in children and adolescents, we were interested in whether authors classified headache in every participant who screened positively for headache or, instead, selectively reported cases fulfilling any specific set of ICHD diagnostic criteria. To clarify this, we re-reviewed all 50 studies included in the most recent review [10] and nine later studies focusing on TTH identified in a literature search up to April 2016 [11, 26–33]. Only five of the 59 studies reliably reported headache that was not classifiable by ICHD criteria [11–15], with prevalences of 2.9–35.5% (mean 18.3 ± 14.1) but with participation proportions ranging between 54.0% and 98.3% (mean 76.2 ± 19.8). In summary, past studies have generally ignored headaches not fulfilling ICHD criteria for migraine or TTH, which nonetheless appear to be common. There is no evidence from the publications that they met our criteria for UdH, but we offer this as a likely possibility.
There are implications in our proposal both for ICHD and for future epidemiological studies in these age groups, which may need to recognise UdH. There are also clinical implications if UdH, while clearly distinct from migraine, is in fact a precursor or immature form of it. We should emphasise that we propose UdH at this stage as a new diagnostic category, not as a new entity. Future research is needed, both to characterise UdH more comprehensively and, especially, to evaluate its prognosis. Only longitudinal cohort studies, ideally into adulthood and perhaps subdividing UdH according to the associated symptoms, can achieve the latter.
Strengths and limitations
The strengths of this study lay in the large numbers of schools, classes and participants, the wide age range, the even distribution of girls and boys, the participants’ geographical and socio-economic diversity, the use of a validated questionnaire presented to the pupils in class by a physician and a high participation proportion.
The study was limited by its convenience-based rather than random sampling. Schools from urban regions (41%) were underrepresented (the national urban proportion is 77% [23]) and those from lower-middle income regions (68%) were overrepresented (Turkey is an upper-middle income country [34]). With respect to the features of UdH, we believe these deviations were not important. We relied on questionnaires, and, as in all such studies, were dependent on participants’ recall and accurate reporting. This is imperfect methodology [20], but it is not easily improved. While young children in particular may report imprecisely, enquiry of parents not only requires greatly increased resources but also, since it involves second-hand reporting, may not be more reliable. Lastly, our study refers to pupils from Turkey, and UdH needs to be assessed in other countries.
Conclusion
Undifferentiated headache characterised by mild headaches lasting < 1 h is common in children and adolescents. It differs measurably with respect to almost all headache features and associated symptoms from both migraine and TTH and has significant adverse impact on QoL. This new diagnostic category in these age groups offers an alternative to jamming an evolving headache disorder that is neither clearly migraine nor clearly TTH into either of these diagnoses. Future longitudinal studies will show whether UdH represents those headaches that are in a shifting state between migraine and TTH before maturing by adulthood into one or the other. Differentiating UdH from migraine and TTH therefore has implications not only for epidemiology but also in routine clinical practice, since patients diagnosed with UdH call for closer follow-up with regard to their headache characteristics and associated symptoms, and a different therapeutic approach.
Acknowledgments
Funding
No external funding was received in support of this study.
Availability of data and materials
The data supporting the conclusions of this article are held electronically in the Department of Neurology, Medical University of Vienna, Vienna, Austria. They are still being analysed, with a number of further publications expected. In due course these data will be made publicly available, but meanwhile will not be shared.
Authors’ contributions
CW contributed to conception and design of the study, analysed the data, contributed to data interpretation and drafted the manuscript. ÇWB conceived and initiated the study and contributed to data interpretation and drafting of the manuscript. DU contributed to design of the study, acted as project coordinator in Turkey and contributed to data interpretation. TSA contributed to data collection, undertook data management and cleansing, and contributed to data analysis and interpretation. UU contributed to data collection, management and cleansing, and to data analysis and interpretation. AT, SIA, TD, FS, GKE, CFD and FB contributed to project management at the survey sites, and to data collection. YBÖ and TA contributed to data management and cleansing, and to data analysis and interpretation. AS contributed to design of the study and drafting of the manuscript. TJS conceived the study, contributed to data interpretation and revised the manuscript critically. All authors commented on and revised the manuscript, and approved the final version.
Competing interests
CW is paid consultant to Curelator, Inc. and has received personal fees from St Jude, Allergan, Pfizer and Apomedica.
AS has received honoraria for presentations at national or international congresses and/or consultation fees from Bayer, Biogen Idec, Genzyme, Merck Serono, Novartis and Teva, and reimbursement of travel expenses and/or registration fees for attendances at national or international congresses from Biogen Idec and GenPharma of Turkey, Genzyme, Merck Serono, Novartis and Teva.
TJS is a director of Lifting The Burden, but otherwise declares no competing interests.
All other authors declare no competing interests.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
References
Associated Data
Data Availability Statement
The data supporting the conclusions of this article are held electronically in the Department of Neurology, Medical University of Vienna, Vienna, Austria. They are still being analysed, with a number of further publications expected. In due course these data will be made publicly available, but meanwhile will not be shared.